<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2577">
  <stage>Registered</stage>
  <submitdate>20/10/2009</submitdate>
  <approvaldate>20/10/2009</approvaldate>
  <nctid>NCT01015014</nctid>
  <trial_identification>
    <studytitle>Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections</studytitle>
    <scientifictitle>First-in-human, Two-stage, Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AN3365 in Single and Multiple Doses in Young Healthy Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AN3365-PK-101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gram-negative Bacterial Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AN3365
Treatment: drugs - Placebo

Active Comparator: AN3365 - 

Placebo Comparator: Saline - 


Treatment: drugs: AN3365
LP, 600 mg vial; reconstituted in Normal Saline

Treatment: drugs: Placebo
0.9% sodium chloride for injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical safety data from 12-lead ECG, clinical laboratory tests, urinalysis, injection site tolerability, spontaneous/elicited adverse event reporting, and vital signs (blood pressure, heart rate, respiratory rate)</outcome>
      <timepoint>Multiple time points up to 14 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of pharmacokinetic parameters to achieve appropriate exposure and estimate the dose proportionality</outcome>
      <timepoint>Multiple time points up to 14 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Young healthy males, 18-45 years (inclusive) of age

          -  Healthy as judged by a responsible physician with no clinically significant
             abnormality

          -  Surgically sterile OR agrees to abstain from sexual intercourse with a female partner
             OR agrees to use a condom and spermicide during sexual intercourse with a female
             partner who uses another form of contraception

          -  Body weight above 50 kg (Body Mass Index between 19 and 30 kg/m2)

          -  Non-smokers

          -  Willing and able to comply with study instructions and commit to all follow-up visits

          -  Ability to understand, agree to and sign the study Informed Consent Form (ICF)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History of serious adverse reactions or hypersensitivity to any drug; or who have a
             known allergy to any of the test product(s) or any components in the test product(s);
             or history of hypersensitivity or allergic reactions to any of the study preparations
             as described in the Investigator's Brochure

          -  Any clinically significant central nervous system, cardiac, pulmonary, metabolic,
             renal, hepatic or gastrointestinal conditions

          -  Abnormal physical findings of clinical significance at the screening examination or
             baseline

          -  History of orthostatic hypotension

          -  Clinically significant abnormal laboratory values

          -  Presence or history of allergies requiring acute or chronic treatment

          -  12 lead ECG abnormalities

          -  Major surgical interventions within 6 months of the study

          -  Has a positive pre-study Hepatitis B surface antigen; positive hepatitis C (HCV)
             antibody or detectable HCV ribonucleic acid (RNA); or positive HIV antibody result

          -  Use of prescription or non-prescription drugs

          -  Has a history of regular alcohol consumption

          -  Loss of 500 mL blood or more during the 3 month period before the study

          -  People that follow vegetarian or vegan diet

          -  Symptoms of a significant somatic or mental illness in the four week period preceding
             drug administration

          -  History of drug abuse or dependence within 12 months of the study

          -  The subject has a positive pre-study alcohol or urine drug screen

          -  Concurrent participation in another drug or device research study or within 60 days of
             post participation in another drug or device study

          -  Considered by the Investigator to be unsuitable candidate for this study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>88</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>CMAX - Adelaide</hospital>
    <postcode> - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic profile
      of an antibacterial compound for treatment of hospital acquired Gram negative infection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01015014</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Lee Zane, MD, MAS</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>